Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1968 1
1980 1
1983 1
1993 2
1994 3
1996 6
1997 2
1998 4
1999 1
2000 3
2001 2
2002 1
2003 1
2004 6
2005 3
2006 4
2007 8
2008 6
2009 5
2010 6
2011 12
2012 11
2013 10
2014 10
2015 15
2016 15
2017 10
2018 15
2019 12
2020 15
2021 13
2022 22
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

232 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Khatibi-baneh
Page 1
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA, Abdelmalek MF, Neff G, Gunn N, Guy CD, Alkhouri N, Bashir MR, Freilich B, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Younes ZH, Bansal M, Baum SJ, Borg B, Ruane PJ, Thuluvath PJ, Gottwald M, Khan M, Chen C, Melchor-Khan L, Chang W, DePaoli AM, Ling L, Lieu HD. Harrison SA, et al. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):603-616. doi: 10.1016/S2468-1253(22)00017-6. Epub 2022 Mar 21. Lancet Gastroenterol Hepatol. 2022. PMID: 35325622 Clinical Trial.
Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD.
Ezhilarasan D. Ezhilarasan D. Metabolism. 2024 Apr 11;155:155912. doi: 10.1016/j.metabol.2024.155912. Online ahead of print. Metabolism. 2024. PMID: 38609038 Review.
In hepatocytes, SARO induces fatty acid beta-oxidation in mitochondria and transcriptionally activates lipid metabolizing genes in peroxisomes. ...This review summarizes the possible molecular mechanism of SARO in the NAFLD....
In hepatocytes, SARO induces fatty acid beta-oxidation in mitochondria and transcriptionally activates lipid metabolizing genes in pe …
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, Moessner E, Ast O, Bruenker P, Grau-Richards S, Schaller T, Seidl A, Gerdes C, Perro M, Nicolini V, Steinhoff N, Dudal S, Neumann S, von Hirschheydt T, Jaeger C, Saro J, Karanikas V, Klein C, Umaña P. Bacac M, et al. Clin Cancer Res. 2016 Jul 1;22(13):3286-97. doi: 10.1158/1078-0432.CCR-15-1696. Epub 2016 Feb 9. Clin Cancer Res. 2016. PMID: 26861458
Re-Definition of the Epidemiology of Cardiac Amyloidosis.
Rossi M, Varrà GG, Porcari A, Saro R, Pagura L, Lalario A, Dore F, Bussani R, Sinagra G, Merlo M. Rossi M, et al. Biomedicines. 2022 Jun 30;10(7):1566. doi: 10.3390/biomedicines10071566. Biomedicines. 2022. PMID: 35884871 Free PMC article. Review.
Silicone and Pyrocarbon Artificial Finger Joints.
Alnaimat FA, Owida HA, Al Sharah A, Alhaj M, Hassan M. Alnaimat FA, et al. Appl Bionics Biomech. 2021 Jun 3;2021:5534796. doi: 10.1155/2021/5534796. eCollection 2021. Appl Bionics Biomech. 2021. PMID: 34188692 Free PMC article. Review.
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.
Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, Dent S, Douglas PS, Durand JB, Ewer M, Fabian C, Hudson M, Jessup M, Jones LW, Ky B, Mayer EL, Moslehi J, Oeffinger K, Ray K, Ruddy K, Lenihan D. Armenian SH, et al. J Clin Oncol. 2017 Mar 10;35(8):893-911. doi: 10.1200/JCO.2016.70.5400. Epub 2016 Dec 5. J Clin Oncol. 2017. PMID: 27918725
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P. Klein C, et al. Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017. Oncoimmunology. 2017. PMID: 28405498 Free PMC article.
232 results